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A B S T R A C T
Alzheimer’s disease (AD) is the most common type of dementia in the elderly. Products of oxidative and
nitrosative stress (OS and NS, respectively) accumulate with aging, which is the main risk factor for AD.
This provides the basis for the involvement of OS and NS in AD pathogenesis. OS and NS occur in
biological systems due to the dysregulation of the redox balance, caused by a deﬁciency of antioxidants
and/or the overproduction of free radicals. Free radical attack against lipids, proteins, sugars and nucleic
acids leads to the formation of bioproducts whose detection in ﬂuids and tissues represents the currently
available method for assessing oxidative/nitrosative damage. Post-mortem and in-vivo studies have
demonstrated an accumulation of products of free radical damage in the central nervous system and in
the peripheral tissues of subjects with AD or mild cognitive impairment (MCI). In addition to their
individual role, biomarkers for OS and NS in AD are associated with altered bioenergetics and amyloid-
beta (Ab) metabolism. In this review we discuss the main results obtained in the ﬁeld of biomarkers of
oxidative/nitrosative stress in AD and MCI in humans, in addition to their potential role as a tool for
diagnosis, prognosis and treatment efﬁcacy in AD.
 2009 Elsevier Ireland Ltd. All rights reserved.
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Alzheimer’s disease (AD) is the most common type of dementia
in the elderly, aging being themain risk factor. Due to the dramatic
increase in the elderly population in developed countries, the
already high prevalence of AD is expected to further rise to up to 13
million cases in USA and over 4 million cases in the EU in 2050
(Small et al., 1997; Hebert et al., 2003). Of the several age-related
diseases, AD is a major socioeconomical and medical challenge
because there is still no signiﬁcant treatment. Therefore, much
research has been undertaken in recent decades to decode the
main pathophysiological changes responsible for AD development.
The main biochemical pathways shown to be associated with the
histophatological and clinical hallmarks of AD appear to be related
to the production andmetabolism of amyloid-beta (Ab) fragments
and neuroﬁbrillary tangles (NFT) (Lambert et al., 1998; Deshpande* Corresponding author at: Institute of Gerontology andGeriatrics, Department of
Clinical and Experimental Medicine, Ospedale Santa Maria della Misericordia,
Piazzale Menghini 1, S. Andrea delle Fratte, 06156 Perugia, Italy.
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E-mail address: mecocci@unipg.it (P. Mecocci).
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doi:10.1016/j.arr.2009.04.002et al., 2006; Cappai and Barnham, 2008). Furthermore, impaired
bioenergetics (Beal, 2005), oxidative stress (Mariani et al., 2005;
Valko et al., 2007) and inﬂammation (Chung et al., 2009) have been
suggested as additional hallmarks. In addition to their individual
role, biomarkers of oxidative and nitrosative stress in AD have been
shown to be associated with altered bioenergetics and Ab
metabolism. For this reason, oxidative and nitrosative damage are
generally accepted as a central process in AD pathophysiology. The
aim of this work is to offer the reader an overview regarding the
main results obtained in the ﬁeld of oxidative/nitrosative stress in
AD in humans. Furthermore, recent data concerning the role of
oxidative/nitrosative stress in mild cognitive impairment (MCI)
will also be assessed. In the following paragraphs, after a brief
introduction on the theory of oxidative stress, we report the main
results of studies on subjects with diagnosis of AD and MCI
assessing the most widely investigated biomarkers of OS and NS in
the brain, cerebrospinal ﬂuid (CSF), blood and urine. We system-
atically searched the PubMed, National Library of Medicine
database for English-language articles published from 1990 to
January 2009 (last accessed on January 31, 2009). Furthermore, we
found additional papers by performing a manual search of the
reference lists of relevant retrieved articles.
Fig. 1.Main ROS and RNS responsible for biomolecules damage in the human body, and their main sources. The most reactive ROS are the superoxide anion and the hydroxyl
radical. Peroxynitrite is themain RNS, but also nitrogen dioxide and nitronium ion exhibit signiﬁcant oxidant properties. ROO: peroxyl radical; the simplest peroxyl radical is
HOO, termed hydroperoxyl radical or perhydroxyl radical. Another important peroxyl radical is LOO, called lipid peroxyl radical. NOSs: nitric oxide synthases.
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Free radicals, reactive oxygen species (ROS) and reactive
nitrogen species (RNS) are molecules or molecular fragments
containing one or more unpaired electrons in atomic or molecular
orbitals, which characterises free radicals with high reactivity
(Halliwell and Gutteridge, 1999). Exogenous agents (such as
photochemical smog, ozone, pesticides, xenobiotics and ionizing
radiation) and a variety of endogenous processes (for example,
mitochondrial respiration, cytochrome P-450 detoxiﬁcation reac-
tions, phagocytic oxidative bursts, and peroxisomal leakage) can
generate signiﬁcant amounts of ROS and RNS in the human body
(Chakravarti and Chakravarti, 2007) (Fig. 1). Indeed, both species of
free radicals are products of normal cellular metabolism.
Mitochondrial oxidative phosphorylation generates the majority
of free radicals in the cell. There is a wide variance in the literature
regarding the percentage of basal mitochondrial oxygen con-
sumption leading to ROS generation, which can be partially
accounted for by the fact that various studies have been conducted
in isolated mitochondria, thus in non-physiological conditions. It
has been proposed that 0.2–2% of the total oxygen consumption is
converted into free radicals in mitochondria (Balaban et al., 2005).
During energy transduction, a small number of electrons ‘‘leak’’ out
from oxygen prematurely, thereby forming ROS, which is mainly
the oxygen free radical superoxide (O2
) (Chance et al., 1979). This
easily reacts with nitric oxide (NO) and forms peroxynitrite
(ONOO), an RNS with very high reactivity (Vatassery, 2004). ROS
and RNS are also normally generated by tightly-regulated
enzymes, such as nitric oxide synthases (NOSs) and nicotinamide
adenine dinucleotide phosphate [NAD(P)H] oxidase isoforms, sincefree radicals take part in many physiological processes. These are
involved in cellular signalling, reactions to stress/noxia (for
example, a defence against infectious agents) and the induction
of mitogenic and apoptotic responses. In addition, NO has effects
on neuronal transmission and synaptic plasticity in the central
nervous system (CNS) (Calabrese et al., 2007; Valko et al., 2007).
However, ROS and RNS can be harmful as they can damage
cellular lipids, sugars, proteins and nucleic acids, thus inhibiting
the latter’s normal function. This damage can compromise cell
viability or induce cellular responses leading to cell death by
necrosis or apoptosis (Valko et al., 2007). Free radical attack against
lipids, proteins, sugars and nucleic acids leads to the formation of
respective bioproducts, which will be discussed in detail below,
and whose detection in ﬂuids and tissues represents the currently
available method of assessing oxidative/nitrosative damage in
several systems (Polidori et al., 2001b).
Living systems have developed mechanisms with which to
control the harmful effects of ROS/RNS. These systems are mainly
based on: (i) the presence of antioxidants (enzymatic and non-
enzymatic); (ii) the repair of injured molecules; and (iii) the
removal of damaged molecules. The wide variety of antioxidant
defence systems helps to prevent and repair ROS and RNS-induced
damage. These antioxidants, however, might themselves become a
target of ROS/RNS damage, their efﬁciency to counteract free
radical hyperproduction thereby being impaired (Beckman and
Ames, 1998). As in the case of the measurable bioproducts of free
radical damage, several compounds of the antioxidant defence
system of the organism can be measured and therefore used as
additional important information regarding the oxidant/antiox-
idant balance of the organism. In ideal circumstances, the rate of
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be comparable to that of its removal or repair. A ﬁne regulation of
ROS/RNS production and neutralization is essential for avoiding
their detrimental effects, and different mechanisms cooperate to
preserve this equilibrium, termed ‘‘redox balance’’ or ‘‘redox
homeostasis’’ (Droge, 2002).
The damage promoted by ROS and RNS is termed oxidative
stress (OS) and nitrosative stress (NS) respectively. These occur in
biological systems when there is a dysregulation of the redox
balance, caused by a deﬁciency of enzymatic and non-enzymatic
antioxidants, and/or an overproduction, or altered spatiotemporal
distribution, of ROS/RNS. On the basis of the most recent
discoveries in this ﬁeld, oxidative and nitrosative stress might
be deﬁned as the disturbance in the balance between ROS/RNS
acting as oxidants and levels of protecting antioxidant defence
systems in favour of the former, potentially leading to damage
(Sies, 1985) and linked to a disruption of redox signalling and
control (Jones, 2006).
A large body of experimental research suggests an important
pathophysiological role of increasedOSandNS in the ageing process
(Sies, 1985; Polidori et al., 2001a; Valko et al., 2007). There are
deﬁnitely certain drawbacks in the defence/repair mechanisms,
since there is evidence of progressive accumulation of oxidative and
nitrosative damage to lipids, proteins, carbohydrates, DNA and RNA
with aging, even in the healthiest individuals, suggesting that aging
is due to a shift from redox regulation to oxidative and nitrosative
damage (Mariani et al., 2005; Chakravarti and Chakravarti, 2007).
Several studies have demonstrated an increase in OS and NS in
several centralnervous systemdiseases, likeAD,Parkinson’sdisease,
amyotrophic lateral sclerosis, Huntington’s disease and cerebro-
vascular diseases (Beal, 2000; Calabrese et al., 2001; Mariani et al.,
2005; Migliore et al., 2005a; Valko et al., 2007).
The brain is particularly vulnerable to oxidative/nitrosative
damage since (i) it contains a high proportion of polyunsaturated
fatty acids, which are highly susceptible to lipid peroxidation, and
catecholamines prone to autoxidation; (ii) it has a high metabolic
activity that requires large amounts of oxygen (the brain uses
approximately 20% of the oxygen consumed by the resting body);
(iii) it is relatively deﬁcient in antioxidant systems with a lower
activityofglutathioneperoxidase (GPx) andcatalase (Cat) compared
to other organs; and (iv) it contains redox-active metals (copper,
iron) that can promote the production of free radicals (Kedar, 2003;
Nunomura et al., 2006b). In neurodegenerative diseases, increased
levelsofOS/NSwithinspeciﬁcbrain regionswhichundergoselective
neurodegeneration have been reported, thereby suggesting that
ROS/RNS can contribute to the development of disease through
primary or secondary pathophysiologic mechanisms.
3. Oxidative and nitrosative damage in AD and MCI
AD is the most common neurodegenerative disorder world-
wide. Neurophatologically, it is characterized by regionalized
neuronal death, synaptic loss, accumulation of intraneuronal NFT
and extracellular senile plaques (SP), and proliferation of reactive
astrocytes in the entorhinal cortex, hippocampus, amygdala and
association areas of frontal, temporal, parietal and occipital cortex.
NFT are formed by intracellular deposits of paired helical ﬁlaments
composed of hyperphosphorylated tau. SP can be present as diffuse
plaques, composed of amorphous extracellular deposits of Ab that
lack neuritis, and as neuritic plaques, which consist of extracellular
deposits of insoluble Ab surrounded by dystrophic neurites,
reactive astrocytes, and activated microglia. Ab is a 39–43 amino
acid peptide derived from the larger Ab precursor protein (APP) by
proteolytic cleavage. Ab 1–40 is themost frequent form of Ab even
if the minor species (i.e., Ab 1–42) has a higher propensity to
aggregate and is greatly enriched in amyloid deposits. Further-more, recent studies suggest that soluble Ab oligomers are present
in the AD brain and they may represent the main toxic form of Ab
(Klein et al., 2001; Walsh et al., 2002; Glabe, 2006).
The fact that age is the main risk factor for AD has provided the
basis for the involvement of oxidative and nitrosative imbalance in
the disease, since products of oxidative and nitrosative damage do
accumulate during aging (Mariani et al., 2005; Valko et al., 2007).
Free radicals promoting OS/NS are thought to play an early
pathophysiological role in AD, and oxidative/nitrosative modiﬁca-
tion to virtually all classes of biomacromolecules has been
described in brain regions susceptible to degeneration in this
disorder, and also in the peripheral tissues of AD subjects (Table 1).
More recently there have beenmultiple studies showing increased
levels of oxidative and nitrosative damage inMCI (Markesbery and
Lovell, 2007). This is a condition in which memory or other
cognitive abilities are slightly abnormal but they coexist with
predominantly normal functions in the activities of daily living and
absence of dementia (Winblad et al., 2004; Artero et al., 2006). MCI
is related to an increased risk of conversion to dementia and it may
be considered, in most of the cases, a prodromal AD (Mariani et al.,
2007). Since intervention in preclinical conditions would have the
greatest public health impact, there is increasing attention
regarding MCI, in order to identify biomarkers that can predict
the risk of conversion to dementia, which could be used tomonitor
responses to therapeutic interventions aimed at reducing the
progression of cognitive decline.
Several post-mortem and in-vivo studies have demonstrated an
accumulation of the products of ROS/RNS damage in AD and MCI
subjects; these substances can be considered biomarkers of
oxidative and nitrosative damage respectively. Biomarkers are
deﬁned as characteristics that can be objectively measured and
evaluated as indicators of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic inter-
vention (Dalle-Donne et al., 2006). The role of OS/NS biomarkers in
AD is not yet totally understood, but it is becoming clear that
several biomolecules could help in clarifying the pathogenesis,
diagnosis and prognosis of AD. In the following paragraphs we
summarize the main ﬁndings regarding the biomarkers of OS and
NS in AD and MCI.
4. Lipids
ROS can attack lipids and extract a hydrogen atom from a
methylene carbon in their side chain. The greater the number of
double bonds in the lipid molecule, the easier will be the removal
of the hydrogen atom. This explains why the polyunsaturated fatty
acid residues of phospholipids are very sensitive to ROS. Lipid
peroxidation, which refers to the oxidative degradation of lipids, is
one of the major outcomes of free radical-mediated injury. The
peroxidation of lipids in plasmalemma or sub-cellular membranes
can be very damaging because it can promote alterations in their
biological properties (such as the degree of membrane ﬂuidity),
and lead to the inactivation of membrane-bound receptors or
enzymes, which in turn may impair normal cellular function and
increase cell permeability (Anzai et al., 1999; Yehuda et al., 2002).
Lipid peroxidation is a self-propagating process that can
proceed until the substrate is consumed or termination occurs,
thus promoting extensive tissue injury (Niki et al., 1993; Porter
et al., 1995). Moreover, various products of lipid peroxidation are
chemically reactive and they covalently modify critical biomo-
lecules like proteins and DNA, thus increasing cellular damage
(Uchida, 2003a). Lipid peroxidation generates a variety of
relatively stable end products, mainly aldehydic by-products,
such as malondialdehyde, and more reactive a,b-unsaturated
reactive aldehydes, such as trans-4-hydroxy-2-nonenal, and 2-
propenal (acrolein) (Pryor and Porter, 1990; Esterbauer et al.,
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2004). Carbonyl-crotonaldehyde is another highly reactive
aldehyde recently studied in AD (Ichihashi et al., 2001;
Kawaguchi-Niida et al., 2006). Other products, derived from the
endocyclization of lipid hydroperoxyl radicals, are isoprostanes
and neuroprostanes; more recently another class of compounds,
named neurofurans, has been identiﬁed (Roberts et al., 1998;
Cracowski et al., 2002; Song et al., 2008). All these substances have
been extensively assessed in brain and biological ﬂuids (CSF,Table 1
Summary of the main ﬁndings relating to biomarkers of oxidative/nitrosative stress in
Biomarkers of lipid peroxidation Main ﬁndings
Malondialdehyde (MDA) and
thiobarbituric acid-reactive
substances (TBARS)
AD: increased levels in the brain (Balazs
Keller et al., 2005). Results on plasma and
et al., 1996; Sinclair et al., 1998; Polidori
2008)
MCI: increased levels in the brain (Keller
Trans-4-hydroxy-2-nonenal (HNE) AD: increased levels in the brain (Montin
2006; Williams et al., 2006). Results on p
Calabrese et al., 2006)
MCI: increased levels in the brain (Butter
Acrolein AD: increased levels in the brain (Calinga
MCI: increased levels in the brain (Willia
Carbonyl-crotonaldehyde (CRA) AD: increased levels in the brain (Kawagu
F2-isoprostanes (F2-IsoPs) AD: increased levels in the brain (Pratico`
Forman et al., 2007) and CSF (Montine et
inconsistent (Feillet-Coudray et al., 1999;
et al., 2004; Irizarry et al., 2007)
MCI: increased levels in the brain (Marke
plasma and urine are inconsistent (Pratic
F4-neuroprostanes (F4-NPs) AD: increased levels in the brain (Nouroo
MCI: increased levels in the brain (Marke
Biomarkers of DNA/RNA oxidation Main ﬁndings
DNA strand breaks AD: increased levels in the brain (Mullaar
et al., 1997; Stadelmann et al., 1998; Adam
8-Hydroxy-20-deoxyguanosine
(8-OHdG)
AD: increased levels in the brain (Mecocc
1999; Lovell and Markesbery, 2001), and
Migliore et al., 2005b)
MCI: increased levels in the brain (Wang
Other biomarkers of DNA oxidation:
8-hydroxyadenine (8-OHA);
2,6-diamino-4-hydroxy-5-
formamidopyrimidine
(Fapy-guanine); 4,6-diamino-5-
formamidopyrimidine
(Fapy-adenine); 5-hydroxycytosine
(5-OHC); 5-hydroxyuracil (5-OHU);
thymine glycol
AD: increased levels in the brain (Lyras et
MCI: increased levels in the brain (Wang
8-Hydroxyguanosine (8-OHG) AD: increased levels in the brain (Nunom
et al., 2005; Shan and Lin, 2006; Lovell an
MCI: increased levels in the brain (Ding e
Biomarkers of protein oxidation/
nitrosylation
Main ﬁndings
Protein carbonyls AD: increased levels in the brain (Hensley
Castegna et al., 2002a, 2002b; Choi et al.,
plasma and peripheral blood cells (Calabr
MCI: increased levels in the brain (Keller
3-Nitrotyrosine (3-NT) and dityrosine AD: increased levels in the brain (Smith e
al., 2003; Sultana et al., 2006e), in the CSF
peripheral blood (Polidori et al., 2004; Ca
MCI: increased levels in the brain (Butter
Other biomarkers of protein oxidation:
glutamic semialdehyde; aminoadipic
semialdehyde; carboxyethyl-lysine;
carboxymethyl-lysine
AD: increased levels in the brain (Pamploplasma, urine), as an index of oxidative damage, in subjects with
AD and MCI.
4.1. Malondialdehyde, trans-4-hydroxy-2-nonenal, acrolein, and
carbonyl-crotonaldehyde
Malondialdehyde (MDA) is a product that can be generated by
thromboxane synthase. However, a report from the Biomarkers of
Oxidative Stress Study showed that peripheral levels of MDAsubjects with AD and MCI.
and Leon, 1994; Palmer and Burns, 1994; Lovell et al., 1995; Marcus et al., 1998;
peripheral blood cells are inconsistent (Ahlskog et al., 1995; Ceballos-Picot
and Mecocci, 2002; Kawamoto et al., 2005; Aybek et al., 2007; Casado et al.,
et al., 2005)
e et al., 1997; Sayre et al., 1997b; Markesbery and Lovell, 1998; Volkel et al.,
lasma and peripheral blood cells are inconsistent (Cecchi et al., 2002;
ﬁeld et al., 2006b; Williams et al., 2006)
san et al., 1999; Lovell et al., 2001; Williams et al., 2006).
ms et al., 2006)
chi-Niida et al., 2006)
et al., 1998; Yao et al., 2003; Markesbery et al., 2005; Casadesus et al., 2007;
al., 1998, 1999a; Pratico` et al., 1998, 2000). Results on plasma and urine are
Pratico` et al., 2000, 2002; Montine et al., 2002; Bohnstedt et al., 2003; Kim
sbery et al., 2005) and CSF (Pratico` et al., 2002; de Leon et al., 2004). Results on
o` et al., 2002; Irizarry et al., 2007)
z-Zadeh et al., 1999; Reich et al., 2001; Markesbery et al., 2005)
sbery et al., 2005)
t et al., 1990; Anderson et al., 1996; Li et al., 1997; Lucassen et al., 1997; Sugaya
ec et al., 1999)
i et al., 1994; Nunomura et al., 1999; Wang et al., 2005), in the CSF (Lovell et al.,
in peripheral blood cells (Mecocci et al., 1998, 2002; Morocz et al., 2002;
et al., 2006) and in peripheral blood cells. (Migliore et al., 2005b)
al., 1997; Gabbita et al., 1998; Wang et al., 2005)
et al., 2006)
ura et al., 1999, 2001, 2004; Shan et al., 2003; Ding et al., 2005, 2006; Honda
d Markesbery, 2008) and in the CSF (Abe et al., 2002)
t al., 2005; Lovell and Markesbery, 2008)
et al., 1995; Lyras et al., 1997; Aksenova et al., 1999; Lauderback et al., 2001;
2004; Keller et al., 2005; Pamplona et al., 2005; Sultana et al., 2006a, 2006b),
ese et al., 2006; Bermejo et al., 2008)
et al., 2005; Butterﬁeld et al., 2006a) and plasma (Bermejo et al., 2008)
t al., 1997b; Su et al., 1997; Hensley et al., 1998; Luth et al., 2002; Castegna et
(Hensley et al., 1998; Tohgi et al., 1999; Ahmed et al., 2005), plasma and
labrese et al., 2006)
ﬁeld et al., 2007)
na et al., 2005)
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of unsaturated lipids (Kadiiska et al., 2005). Thiobarbituric acid-
reactive substances (TBARS) mainly measure the level of MDA
since MDA reacts with thiobarbituric acid (TBA) to form the MDA–
TBA adduct (Gutteridge, 1982). TBARS assessment by spectro-
photometric assay has been widely used to quantify lipid
peroxidation, but it has been criticized due to its lack of speciﬁcity,
sensitivity, and reproducibility (Pincemail et al., 1996). The direct
assessment of MDA by high-performance liquid chromatography
(HPLC) is more speciﬁc but this approach does not deduce all the
limitations of this biomarker (Gutteridge and Halliwell, 1990; Gotz
et al., 1993; Sultana et al., 2006d); HPLC is also used to assess the
MDA–TBA complex (Lepage et al., 1991).
Another product of free radical damage to lipids is trans-4-
hydroxy-2-nonenal (HNE), which is one of the more toxic products
of lipid peroxidation. MDA and HNE are able to covalently modify
proteins, thus affecting their function, and MDA can lead to the
formation of immunogenic MDA-modiﬁed peptide adducts
(Stocker and Keaney, 2004; Butterﬁeld et al., 2006b). MDA can
impair mithocondrial respiration, inhibiting the activity of several
mithocondrial enzymes (complexes I, II, V, pyruvate dehydrogen-
ase, a-ketoglutarate dehydrogenase, superoxidodismutase) and
promoting ROS generation (Long et al., 2008). This lead to neuronal
mitochondrial damage, which is believed to be amajor contributor
to aging and neurodegenerative diseases (Reddy and Beal, 2008).
HNE can interfere with the synthesis of DNA, RNA and proteins,
alter cell metabolism and signalling, and mediate Ab-induced
oxidative damage. Some studies suggest that MDA and HNE can
promote the degeneration of cholinergic neurons and Ab
aggregation (Mark et al., 1995; Keller et al., 1997; Pedersen
et al., 1999; Lauderback et al., 2001; Butterﬁeld et al., 2006b; Chen
et al., 2007; Siegel et al., 2007), and there is also evidence that
increased lipid peroxidation can promote amyloidogenesis
through the up-regulation of b-site APP cleavage enzyme 1
(BACE1) (Chen et al., 2008). Acrolein is the most reactive aldehydic
product derived from the metal-catalyzed oxidation of polyunsa-
turated fatty acids, including arachidonic and docosahexanoic
acids. Due to its high reactivity, acrolein can promote the formation
of protein adducts, thus inhibiting protein functions, and this can
promote presynaptic damage (LoPachin et al., 2008). Acrolein
preferentially reacts with lysine residues, which are prominent
components of tau protein, and the presence of acroilein adducts
has been described in neuroﬁbrillary tangles (Calingasan et al.,
1999). In vitro data has shown that acrolein can induce tau
oligomerization, thus promoting the production of aggregates of
paired helical ﬁlaments. The process is accelerated if tau is
phosphorylated, suggesting that acrolein can promote neuroﬁ-
brillary tangles formation (Kuhla et al., 2007). Furthermore,
acrolein can modify DNA and promote lipid peroxidation
(Esterbauer et al., 1991; Uchida et al., 1998; Lovell et al., 2000a).
Different studies have demonstrated signiﬁcantly increased
levels of MDA and TBARS in AD brains compared to controls,
especially in regions where NFT and SP are more prominent (e.g.,
temporal lobe, hippocampus, pyriform cortex, and amygdala)
(Subbarao et al., 1990; Balazs and Leon, 1994; Palmer and Burns,
1994; Lovell et al., 1995; Marcus et al., 1998; Keller et al., 2005).
Two studies failed to ﬁnd differences in levels ofMDA-TBA adducts,
assessed by HPLC, in different brain regions of AD subjects, as
compared to controls (Hayn et al., 1996; Lyras et al., 1997). Other
studies have revealed that, even if basal brain levels of TBARS were
not different between AD brains and controls, there was an
increased TBARS production in the AD brain after incubation with
pro-oxidant substances, suggesting that AD subjects are more
vulnerable to lipid oxidation (Hajimohammadreza and Brammer,
1990; McIntosh et al., 1997). Although the concentration of TBARS
in the hippocampus of AD patients was not increased compared tocontrols, in one study it was related to APOE genotype, since in AD
patients the highest TBARS levels were found in APOE e4 carriers,
thereby suggesting that APOE genotype affects the extent of the
oxidative stress-induced damage and that the increased risk to
develop AD in e4 carriers could be, at least in part, mediated
through an increased susceptibility to lipoperoxidation (Ramas-
samy et al., 2000).
Increased levels of free HNE (Markesbery and Lovell, 1998) and
HNE–protein adducts (Montine et al., 1997; Sayre et al., 1997b)
have been described in the brains of AD patients compared with
control subjects; HNE particularly accumulated in regions affected
by neurodegenerative processes, including the amygdala, hippo-
campus and parahippocampal gyrus. Volkel et al. (2005, 2006)
have developed a sensitive method, based on mass spectrometry
(MS) analysis, with which they demonstrated increased levels of
HNE–glutathione conjugates in different brain regions affected by
neurodegeneration in AD patients, compared to control samples.
Another research group used MS analysis to show increased HNE
and acrolein levels in the hippocampus, parahippocampal gyrus,
superior and middle temporal gyrus of subjects with early AD,
compared to control subjects (Williams et al., 2005, 2006). The
presence of increased levels of acrolein-protein adducts in the AD
brain has also been demonstrated in earlier studies (Calingasan
et al., 1999; Lovell et al., 2001). The levels of these biomarkers may
be altered by increased production and decreased metabolism:
indeed the activity of some of the major metabolizing enzymes for
these products of lipid peroxidation is altered in the diseased brain
regions of subjects with AD. These data suggest that the
detoxiﬁcation of lipid-aldehydes could be impaired in AD, but
conclusive data are not yet available (Picklo and Montine, 2007).
Free HNE has also been assessed in ventricular CSF from patients
with AD, and its levels were found to be signiﬁcantly elevated
compared to age-matched controls, while no differences were
detected in HNE–protein adducts (Lovell et al., 1997). Free
carbonyl-crotonaldehyde (CRA) is an highly reactive aldehydic
intermediate, able to cause carbonylation, and then dysfunction, of
a wide range of cellular proteins; CRA also promotes glutathione
(GSH) depletion and DNA damage (Esterbauer et al., 1991; Reddy
et al., 2002; Luczaj and Skrzydlewska, 2003). CRA has been recently
described as a product of lipid peroxidation which is increased in
the hippocampal region of AD brain, compared to control subjects;
CRA mainly accumulates in glial cells, where it promotes the
formation of CRA-protein adducts (Kawaguchi-Niida et al., 2006).
Biomarkers of lipid peroxidation have also been explored in
blood with conﬂicting results. Different authors have demon-
strated increased levels of TBARS in serum/plasma (Ozcankaya
andDelibas, 2002; Polidori andMecocci, 2002; Aybek et al., 2007),
and in blood cells (erythrocyte) (Serra et al., 2001; Kawamoto
et al., 2005) from AD subjects, compared to controls, whereas
other studies did not conﬁrm these ﬁndings (Ahlskog et al., 1995;
Ceballos-Picot et al., 1996; Fernandes et al., 1999; Baldeiras et al.,
2008). Polidori and Mecocci (2002) showed that not only was the
TBARS plasma level higher in AD subjects than in age-matched
controls, but plasma exposure to a free radical generator
promoted a greater production of TBARS in AD patients. This
was also associated with an increased rate of consumption of
plasma antioxidants (e.g. ascorbate), thereby suggesting an
enhanced plasma susceptibility to oxidative damage in AD
patients.
Free MDA has been reported in various studies to be higher in
plasma and erythrocyte from subjects with AD, compared to
controls (Bourdel-Marchasson et al., 2001; Casado et al., 2008;
Martin-Aragon et al., 2009), while other investigations have failed
to show any differences in serum MDA in AD subjects (Sinclair
et al., 1998; McGrath et al., 2001). Cecchi et al. (2002) found
increased levels of MDA and HNE in peripheral cells (skin
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AD, carrying APP and presenilin-1 (PS-1) gene mutations; in the
same study no differences in MDA and HNE levels were identiﬁed
between sporadic AD and control subjects. There are also
conﬂicting results regarding HNE: some authors have demon-
strated elevated plasma levels of HNE in AD subjects, compared to
controls (McGrath et al., 2001; Calabrese et al., 2006), while others
did not observe any difference (Sinclair et al., 1998).
The presence of lipid peroxidation has also been investigated in
subjects with MCI. Keller et al. (2005) have shown increased levels
of TBARS and MDA in the superior and middle temporal gyri of
subjects with amnestic MCI, and other studies have demonstrated
increased HNE levels in the hippocampus, inferior parietal lobule,
temporal lobe and cerebellum of patients with amnestic MCI
(Butterﬁeld et al., 2006b; Williams et al., 2006). Williams et al.
(2006) have revealed that acrolein levels were also signiﬁcantly
elevated in the superior and middle temporal gyri in MCI subjects;
both HNE and acrolein were increased compared with healthy
controls, and there was no difference between MCI and early AD
subjects, which were analyzed in the same study (Williams et al.,
2006).
A few of the above cited studies documenting the presence of
increased levels of lipid oxidative damage in AD and MCI, both in
the CNS and peripheral ﬂuids, may have shortcomings that need to
be taken into account. First, the amount of lipid peroxidation
products is affected by several physiological and non-physiological
conditions, such as lifestyle: acrolein and crotonaldehyde are
largely present in cigarette smoke (Nath et al., 1998), and lipid
hydroperoxides and aldehydes can also be absorbed from the diet
and excreted in urine, in turn inﬂuencing MDA and HNE
assessment in plasma (Wilson et al., 2002). Secondly, comorbidity
is another element that needs to be considered: levels of TBARS,
MDA and HNE are increased in the presence of diabetes (Ahlskog
et al., 1995;Martin-Gallan et al., 2003), chronic renal failure (Siems
et al., 2002; Dirican et al., 2007), cardiovascular diseases (Uchida,
2000; Nakamura et al., 2005; Sathiyapriya et al., 2007), and cancer
(Bartsch and Nair, 2005; Kosova et al., 2007; Nayak and Pinto,
2007). In conclusion, the value of these biomarkers when studying
MCI and AD, is strictly linked to the possibility of taking into
account potential confounders (e.g. diet, smoking, comorbidity).
Furthermore, it is also important to consider more than one
biomarker in order to improve the identiﬁcation of changes in the
status of lipid peroxidation as related to neurodegeneration.
4.2. Isoprostanes, neuroprostanes and neurofurans
Of the isoprostanes, F2-Isoprostanes (F2-IsoPs) have been
extensively studied as biomarkers of lipid oxidative damage. They
are considered as ideal candidates for the accurate quantitative
assessment of OS status and lipid peroxidation due to their
chemical stability in-vivo and ex-vivo, and minimal metabolism
in-situ (Roberts and Morrow, 2002; Basu, 2004; Halliwell and
Whiteman, 2004; Montuschi et al., 2004; Morrow, 2005). F2-IsoPs
include 64 different products containing an F-type prostane ring,
generated in-vivo by the non-enzymatic free radical-mediated
peroxidation of esteriﬁed arachidonic acid (AA), which is
distributed throughout the white and grey matter of CNS; F2-
IsoPs are thereafter cleaved and released into the circulation by
phospholipases before excretion in the urine as free isoprostanes
(Morrow et al., 1992; Montine et al., 2007). F2-IsoPs can be
measured by different techniques: MS methods [gas chromato-
graphy–MS (GC–MS); GC–tandem-MS (GS–MS/MS), liquid chro-
matography MS (LC–MS), LC–MS/MS] which are considered the
gold standard, and immunological methods [radioimmunoassay
(RIA) and enzyme immunoassay (EIA)]. There is still little
information regarding the precision and accuracy of theseimmunological techniques, but this area of research is expanding
since these methods are more easily available than MS (Dalle-
Donne et al., 2006; Montine et al., 2007).
Increased levels of F2-IsoPs have been detected in different
brain regions of patientswith AD compared to controls: the frontal,
parietal and temporal lobes and hippocampus are involved, while
the level of F2-IsoPs in the cerebellum (a region rarely affected by
AD) was not found to increase (Pratico` et al., 1998; Reich et al.,
2001; Yao et al., 2003; Markesbery et al., 2005; Forman et al.,
2007). One study has demonstrated the speciﬁc cellular localiza-
tion of F2-IsoPs which mainly accumulate in neuronal cells. Other
cellular types like glia are involved in the build up of F2-IsoPs but
the main localization in neurons suggests that lipid peroxidation
takes part in the pathogenetic process leading to neurodegenera-
tion, being not merely a simplemarker of reactive gliosis occurring
late on in the disease (Casadesus et al., 2007).
Average levels of F2-IsoPs were also found increased in post-
mortem ventricular CSF obtained from AD subjects, compared to
age-matched controls (Montine et al., 1998; Pratico` et al., 1998).
Montine et al. (1999b) observed that the concentration of
ventricular CSF F2-IsoPs in patients with AD signiﬁcantly
correlated with indices of neurodegeneration, such as a reduction
in brain weight and degree of cortical atrophy, suggesting that
brain lipid peroxidation is associated with the progression of AD.
Studies in-vivo have conﬁrmed the presence of increased levels in
CSF F2-IsoPs in AD subjects, compared to age-matched controls. In
these studies F2-IsoPs were measured in lumbar CSF, where they
were lower compared to ventricular CSF, probably due to a
rostrocaudal gradient and an earlier stage of the disease in patients
enrolled in the in-vivo CSF assessment, while post-mortem studies
were conducted on patients with an advanced stage of the disease
(Montine et al., 1999a,c; Pratico` et al., 2002). The concentration of
CSF F2-IsoPs seems to correlate with clinical severity (Pratico` et al.,
2000) and other biomarkers of the disease, like Ab42 and the
concentration of tau in CSF (Pratico` et al., 2000; Montine et al.,
2001). This suggests that, even if the role of biochemicalmarkers in
diagnosing AD has not yet been well-deﬁned, the quantiﬁcation of
CSF F2-IsoPs together with other biomarkers may enhance the
accuracy of the laboratory identiﬁcation of AD (Montine et al.,
2001). CSF isoprostanes are potentially useful for detecting early
AD, representing an index of brain oxidative damage which could
be helpful for monitoring the course of neurodegeneration and
quantifying the effectiveness of experimental therapeutics, like
antioxidant treatments. Indeed, Quinn et al. (2004) demonstrated a
longitudinal increased in CSF F2-IsoPs in AD patients and, in the
same study, they found thata-tocopherol supplementation, only if
associated with vitamin C intake, was able to reduce the
progressive raise in CSF F2-IsoPs in those subjects. However, more
studies are required to conﬁrm these data and to evaluate if a
reduction in the levels of CSF isoprostanes is related to a delay in
the neuropathological and clinical progression of AD.
The quantiﬁcation of isoprostanes in the plasma and urine of AD
patients has yielded conﬂicting results. Pratico` et al. (2000, 2002)
have found elevated levels of F2-IsoPs in the urine and blood of AD
patients, that were correlated with the concentration of CSF F2-
IsoPs. Other groups of researchers have conﬁrmed the presence of
increased isoprostanes urinary levels in AD (Tuppo et al., 2001;
Kim et al., 2004), but further studies by other researchers did not
(Waddington et al., 1999; Bohnstedt et al., 2003). Another
laboratory showed an increase in the levels of plasma isoprostanes
in AD (Waddington et al., 1999), unconﬁrmed by other researchers
(Feillet-Coudray et al., 1999; Irizarry et al., 2007). Finally, Montine
et al. (2000, 2002) observed no difference in levels of plasma and
urinary F2-IsoPs in AD compared to controls; methodological
differences could explain these conﬂicting results. Furthermore,
multiple physiological and pathological processes inﬂuence the
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activity, smoker or non-smoker, cardiovascular diseases, diabetes).
Accordingly, it is necessary to control for confounding when
analysing the level of isoprostanes in blood and urine (Morrow
et al., 1995; Dalle-Donne et al., 2006).
F2-IsoPs have also been investigated inMCI and increased levels
of F2-IsoPs have been documented in different brain regions of MCI
subjects in comparison to cognitively normal individuals (Mar-
kesbery et al., 2005). These results were not conﬁrmed in a recent
study by Forman et al. (2007), who have shown higher levels of F2-
IsoPs in the brains of AD patients in comparison to controls, but no
difference between MCI and, respectively, AD or cognitively
normal subjects. Interestingly, in this study F2-IsoPs levels were
related to both senile plaque and the burden of NFT, but not to
clinical diagnosis. The association of isoprostanes level with
neuropathological hallmarks, like plaques and tangles, suggests
that lipid peroxidation accurately reﬂects the burden of AD
pathology. Another study has revealed no difference in brain levels
of F2-IsoPs among fronto-temporal dementia cases and controls
(Yao et al., 2003). Since MCI is a heterogeneous clinical entity that
may include not only prodromal AD but also the preclinical stage of
other types of dementia (Winblad et al., 2004), these results
suggest that lipid peroxidation could be a key feature in AD. Thus, it
is possible that a signiﬁcant increase in lipid peroxidation could be
detected only in MCI cases which represent prodromal AD.
This hypothesis is supported by studies which identiﬁed
increased CSF F2-IsoPs in subjects with MCI, compared to age-
matched controls (Pratico` et al., 2002; de Leon et al., 2004, 2007).
Particularly, a small longitudinal study showed that not only
isoprostanes were increased in CSF of MCI subjects, but there was
also a signiﬁcant raise in levels of F2-IsoPs in this group after 12
months, compared to cognitively normal subjects (de Leon et al.,
2004). Another study found that the rate of increase of CSF F2-IsoPs
was higher in MCI subjects who converted to AD compared to
healthy controls and stable MCI (Brys et al., 2009). de Leon et al.
(2006, 2007) conﬁrmed that a longitudinal evaluation of CSF F2-
IsoPs could predict future AD development in amnestic MCI, and
the decline to MCI in cognitively normal subjects: in both cases
there was a higher rate of increase in CSF F2-IsoPs compared to
stable subjects. In these studies it has also been also shown that
isoprostane assessment in CSF, together with other clinical
markers [neuropsychological evaluation; hippocampal atrophy
detected with Magnetic Resonance Imaging; CSF levels of
phosphorylated tau (P-tau231)], increases the accuracy of diag-
nosingMCI. The plasma or urinary assessment of F2-IsoPswould be
easier for the longitudinal monitoring ofMCI subjects, but again, as
demonstrated in AD subjects, the data on plasma and urinary F2-
IsoPs in MCI are inconsistent. One study showed an increase in the
levels of F2-IsoPs in plasma and urine in MCI patients compared
with control subjects (Pratico` et al., 2002), but another study did
not conﬁrm these ﬁndings (Irizarry et al., 2007).
Other compounds studied in AD and MCI as biomarkers of lipid
peroxidation are neuroprostanes, particularly F4-neuroprostanes
(F4-NPs). Neuroprostanes are F2-IsoPs-like molecules, and they are
stable products of free radical damage to docosahexanoic acid
(DHA). Their name derives from the high levels of DHA in the brain,
particularly in the grey matter where it comprises approximately
25–35% of the total amount of fatty acids in aminophospholipids
(Skinner et al., 1993). DHA is synthesized mainly by astrocytes,
after which it is secreted and taken up by neurons (Moore et al.,
1991). F4-NPs increase in different brain regions of subjects with
AD and MCI compared to controls (Nourooz-Zadeh et al., 1999;
Reich et al., 2001; Markesbery et al., 2005), and there is also
evidence that neuroprostanes could inhibit the proteasome
function in AD, thus impairing the clearance of oxidized proteins
(Cecarini et al., 2007). Once formed, F4-NPs can undergo hydrolysisthereafter being released into biological ﬂuids. A small study found
that CSF F4-NPs levels in patients with ADwere signiﬁcantly higher
than age-matched control subjects (Roberts et al., 1998).
Finally, neurofurans (nFs), are a novel family of lipid peroxida-
tion biomarkers, comprising DHA-derived peroxidation products
containing a substituted tetrahydrofuran ring (Arneson and
Roberts, 2007). Preliminary studies showed increased levels of
nFs in the brain cortex of a mouse model of Alzheimer’s disease,
thus suggesting that nFs may be useful biomarkers for this
neurodegenerative disorder (Song et al., 2008).
5. Nucleic acids
Nucleic acids [nuclear DNA (nDNA), mitochondrial DNA
(mtDNA), and RNA] are one of the cellular macromolecules
damaged by free radicals. Mitochondrial DNA is more susceptible
to OS/NS compared to nDNA (Barja, 2004). This is due to: (i) its lack
of protective histones; (ii) its high information density, due to the
absence of introns; (iii) its close proximity to the inner
mitochondrial membrane, where ROS are generated; and (iv)
the presence of limited repair mechanisms (Clayton et al., 1974;
Linnane et al., 1989; Ames et al., 1993; Mecocci et al., 1994;
Wallace, 2005; LeDoux et al., 2007).
Neurons are highly differentiated, post-mitotic cells, and they
survive as long as the organism does. Thus, the oxidative/
nitrosative modiﬁcations of RNA, DNA and, particularly, mito-
chondrial DNA, are thought to play a key role in the selective
neuronal loss associated with aging and neurodegeneration
(Barzilai, 2007; Moreira et al., 2008). In AD and in MCI, an
accumulation of oxidative/nitrosative damage in nucleic acid is
observed in the brain and in peripheral tissues, indicating an
increased level of oxidative/nitrosative stress and/or a decreased
capacity to repair the damage. Several groups of researchers have
investigated the DNA repair mechanisms in AD patients, with
conﬂicting results. Numerous studies have conﬁrmed a decrease in
DNA repair efﬁciency in AD (Parshad et al., 1996; Lovell et al.,
2000b; Iida et al., 2002; Morocz et al., 2002; Jacobsen et al., 2004;
Weissman et al., 2007; Shao et al., 2008) and also in subjects with
MCI (Shao et al., 2008), whereas others did not (Kinsella et al.,
1987; Edwards et al., 1989).
5.1. DNA damage
ROS, and mainly the hydroxyl radical (OH), can react with all
components of theDNAmolecule (the purine and pyrimidine bases
and the deoxyribose backbone), causing different kinds of damage,
such as base or sugar lesions, single-strand breaks, abasic sites
formation, and DNA–DNA or DNA–protein cross-links (Halliwell
and Gutteridge, 1999; Dizdaroglu et al., 2002). DNA can also
undergo nitrosative/nitroxidative damage by RNS, which may
promote nitration and deamination of purines (Malinski, 2007).
DNA oxidation/nitroxidation can produce mutations and impair
transcriptional and post-transcriptional pathways, thus compro-
mising protein synthesis (Colurso et al., 2003). Damage to nDNA
and mtDNA may promote neuron death through defects in
oxidative phosphorylation and cell metabolism (Moreira et al.,
2008). There is also evidence that in neurons DNA damage could
induce an abortive re-entry in the cell cycle, leading to apoptosis
(Becker and Bonni, 2004; Kruman, 2004; Fishel et al., 2007).
DNA injury has been investigated in AD and MCI subjects,
starting with the analysis of DNA strand breaks, which may be an
expression of DNA oxidation. Subsequent studies have assessed
the presence of speciﬁc oxidized DNA bases and at least 20
different bases adducts derived from DNA oxidation have been
described (Dizdaroglu et al., 2002). The most investigated DNA
adduct is 8-hydroxy-20-deoxyguanosine (8-OHdG) which derives
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potential, is readily oxidized (Lovell and Markesbery, 2007). DNA
damage has been evaluated with several techniques: immunoas-
say; Comet assay; capillary electrophoresis; HPLC; GC–MS; and
LC–MS. MS methods permit the identiﬁcation of a wide range of
base adducts in a single run, thus giving amore complete picture of
DNA oxidation, but this techniques can be skewed by the
artefactual oxidation of DNA (Lyras et al., 1997; Lovell and
Markesbery, 2007). Methods to assess purine nitration and
deamination have not yet been completely validated and they
are not extensively used in studies on humans (Halliwell and
Whiteman, 2004; Dalle-Donne et al., 2006).
Several post-mortem studies have revealed signiﬁcant DNA
fragmentation (strand breaks) in the brain of AD subjects
compared to non-demented controls. An at least two-fold increase
in DNA strand breaks has been detected in the brain cortex of
patients with AD (Mullaart et al., 1990) and many investigators
have conﬁrmed a higher presence of neuronal DNA fragmentation
in those areas which are more vulnerable to neurodegeneration,
such as the temporal isocortex, hippocampus, midfrontal gyrus,
and entorhinal cortex (Su et al., 1994; Anderson et al., 1996; Li
et al., 1997; Lucassen et al., 1997; Sugaya et al., 1997; Stadelmann
et al., 1998; Adamec et al., 1999; Colurso et al., 2003). Su et al.
(1997) have demonstrated that the build-up of DNA strand breaks
in AD brain was associated with increased levels of nitrotyrosine, a
marker of protein nitroxidative damage, and they suggested that
peroxynitrite could promote DNA damage.
Mecocci et al. (1993) were the ﬁrst group to demonstrate a
progressive age-related accumulation of 8-OHdG in the cerebral
cortex of cognitively normal subjects, aged 42–97 years. The
amount of 8-OHdGwas higher inmtDNA, as comparedwith nDNA,
and the author proposed that such damage could contribute to an
age-dependent increase in the incidence of neurodegeneration.
This hypothesis was reinforced in a subsequent study, in which
Mecocci et al. (1994) provided preliminary proof regarding
increased DNA oxidation in AD by assessing 8-OHdG. Using HPLC
assay, the research group detected elevated levels of 8-OHdG in
post-mortem brain tissue from AD subjects, compared to age-
matched controls. The 8-OHdG build-upwas signiﬁcantly higher in
mtDNA compared to nDNA, both in cases and controls. There was a
threefold increase in oxidative damage to mtDNA in the AD
samples, compared to controls, and themostmarked changeswere
in the parietal cortex; the levels of 8-OHdG in nDNA were slightly
increased in AD in comparison with normal subjects, but the
difference was not signiﬁcant.
Nunomura et al. (1999), by means of an immunocytochemical
assay, have conﬁrmed the presence of elevated 8-OHdG levels in
neurons from AD subjects, compared to healthy controls. This
increase involved brain areas typically affected by AD neurode-
generation: the hippocampus, subiculum, entorhinal cortex,
frontal, temporal and occipital neocortex, while the level of 8-
OHdG in the cerebellum displayed no differences between AD and
controls. Further, the presence of oxidized nucleosides was
inversely related to NFT content, thereby suggesting that DNA
oxidation could precede lesion formation. There exist only two
studies which detected unaltered levels of 8-OHdG in AD brain,
compared to controls using an HPLC assay (Te Koppele et al., 1996;
Seidl et al., 1997). Increased levels of 8-OHdG have also been
demonstrated in intact DNA which was extracted from the
ventricular CSF of patients with AD, compared to controls. This
was concurrent with a depletion of free 8-OHdG, a marker of DNA
repair activity, thus suggesting that AD is characterized by
increased ROS production and decreased DNA repair capacities
(Lovell et al., 1999; Lovell and Markesbery, 2001).
The higher level of DNA oxidation in the AD brain has been
conﬁrmed by other research groups who, using MS methods,assessed different products of DNA damage, arising from all four
DNA bases: 8-OHdG, that has been conﬁrmed to be the main
product of DNA oxidation (Gabbita et al., 1998; Wang et al., 2005);
2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy-guanine),
a degradation product of 8-OHdG; 8-hydroxyadenine (8-OHA);
4,6-diamino-5-formamidopyrimidine (Fapy-adenine), a degrada-
tion product of 8-OHA; 5-hydroxycytosine (5-OHC); and 5-
hydroxyuracil (5-OHU), a degradation product of cytosine, and
thymine glycol (Lyras et al., 1997; Gabbita et al., 1998;Wang et al.,
2005). Lyras et al. (1997) used GC–MS to demonstrate a general-
ized increase in DNA oxidative damage in the AD brain. They found
increased levels of various (8-OHdG, 8-OHA, thymine glycol, Fapy-
guanine, 5-OHC, 5-OHU, and Fapy-adenine), but not all, oxidized
DNA bases, in the parietal, temporal, occipital, and frontal lobes,
superior temporal gyrus, and hippocampus. The damage was
higher in the parietal lobe, where a signiﬁcant statistical difference
between AD and controls on 8-OHdG, 8-OHA and 5-OHC was
identiﬁed, but the level of DNA oxidative damage in the temporal
lobe was higher than in other brain regions in controls and the AD
brain. Lovell and co-workers have conﬁrmed these ﬁndings: using
GC–MS they evaluated nDNA damage, showing increased levels of
8-OHdG, 8-OHA, 5-OHC, and 5-OHU in the neocortex of AD brain.
They also demonstrated that the cerebellum, which is usually
spared in AD, was fairly unaffected by DNA oxidation. The increase
in each biomarker of nDNA oxidative damage was dissimilar in
different brain regions, but overall the number of oxidatively
modiﬁed bases was remarkably higher in AD temporal, parietal
and frontal lobes, compared to age-matched controls. As with
Lyras’ study, the temporal lobe was found to be the principal target
of OS; in this region the ratio of oxidatively modiﬁed bases per
number of bases was 1:600 in AD and 1:2100 in controls.
Speciﬁcally, it was 1:900 in AD vs 1:2800 in controls, and 1:700 in
AD vs 1:2400 in controls in parietal and frontal lobe respectively
(Gabbita et al., 1998).
More recently, Lovell’s group corroborated these results in a
study, where they also demonstrated that mtDNA had approxi-
mately 10-fold higher levels of oxidized bases than nDNA, thus
suggesting higher levels of OS in mitochondria (Wang et al., 2005).
Furthermore, the author performed the same analysis in subjects
with amnestic MCI, revealing statistically signiﬁcant elevations of
8-OHdG in the nDNA of frontal and parietal lobes, and the mtDNA
from temporal lobes, compared to normal control subjects. They
also observed higher levels of 8-OHA, 5-OHC and Fapy-adenine in
nDNA, and Fapy-adenine in mtDNA from all three neocortical
regions of MCI compared to controls. DNA oxidation was higher in
mtDNA than in nDNA, and no differences were observed between
MCI and controls in the amount of DNA oxidation in the
cerebellum. Interestingly, levels of DNA base adducts in MCI were
not signiﬁcantly different from those observed in AD subjects,
suggesting that DNA oxidation is an early event in the pathogenesis
of neurodegeneration in AD (Wang et al., 2006).
In subjects with AD, the biomarkers of DNA oxidative damage
derived from the interaction between nucleic acid and products of
lipid peroxidation, such as acrolein and HNE, have been also
investigated. An attack on DNA by these aldehydic compounds
leads to the formation of bulky exocyclic adducts, which can
promote DNA–DNA and DNA–protein cross linking and impair
transcription factors binding (Kozekov et al., 2003; Liu et al., 2006;
Lovell and Markesbery, 2007). Liu et al. (2005) have shown a
statistically signiﬁcant two-fold increase in the mean level of
acrolein-deoxyguanosine adduct in nDNA, isolated from the
hippocampus of eight AD subjects, compared to age-matched
controls. In contrast, levels of the HNE–deoxyguanosine adduct in
nDNA from the inferior parietal lobule and hippocampus of AD did
not signiﬁcantly differ compared to control subjects (Liu et al.,
2006). These ﬁndings are consistent with earlier studies of Gotz
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deoxyguanosine adduct in nDNA isolated from the hippocampus,
parietal cortex and cerebellum of AD subjects, in comparison with
controls.
Increased levels of DNA oxidation have been demonstrated not
only in the CNS, but also in the peripheral tissues of AD individuals,
suggesting the systemic nature of oxidative damage in AD, even
though most of the pathological changes are in the brain. Using
HPLC analysis, Mecocci et al. (1998, 2002) have observed in AD a
signiﬁcantly higher lymphocyte concentration of 8-OHdG at DNA
level, compared to age-matched controls. Moreover, there was a
signiﬁcant inverse relationship in AD patients between lympho-
cyte 8-OHdG content and the plasma level of several non-
enzymatic antioxidants (mainly carotenoids), which were sig-
niﬁcantly depleted in comparison to control subjects. The
increased presence of markers of DNA oxidation (in addition to
CNS) has been conﬁrmed by different authors, who applied a
modiﬁed version of the Comet assay (single-cell gel electrophor-
esis) for the detection of oxidised purines and pyrimidines in the
peripheral lymphocytes and leukocytes of AD patients, and the
same ﬁndings have also been demonstrated in MCI subjects
(Morocz et al., 2002; Kadioglu et al., 2004; Migliore et al., 2005b).
One study investigated the presence of urinary oxidized nucleo-
sides in AD subjects, showing increased levels compared to control
individuals (Lee et al., 2007). Many authors agree that oxidized
purines and pyrimidines in lymphocyte DNA, whilst useful, cannot
be used as a unique diagnostic biomarker for AD, since there is an
overlap in the levels of purine and pyrimidine oxidation between
AD and controls; increased DNA oxidation is not speciﬁc to AD but
it is also present in other neurodegenerative conditions, such as
Parkinson’s disease and amyotrophic lateral sclerosis (Migliore
et al., 2005a).
5.2. RNA damage
RNA is more vulnerable to oxidative damage than DNA,
probably because (unlike DNA) RNA is mostly single-stranded
and its bases are not protected by hydrogen bonding; furthermore,
RNA is not covered with protective histones (Fiala et al., 1989;
Wamer andWei, 1997; Bregeon and Sarasin, 2005). RNAmolecules
are intermediaries in the transfer of genetic information from DNA
to proteins, and they are of importance in regulating gene
expression. Oxidative injury to RNA may interfere with correct
base pairing, compromise the accuracy of transcription and
translation, thus prejudicing normal protein synthesis; it could
also promote protein aggregation (Nunomura et al., 1999; Shan
et al., 2003; Bregeon and Sarasin, 2005; Szymanski et al., 2005).
Studies on neuronal cultures have indicated that messenger RNA
(mRNA) oxidation may be an important factor initiating the
cascade of neurodegeneration (Shan et al., 2007). An analysis of
RNA oxidative damage has been performed on the CNS (brain
tissue, CSF) and serum of patients with AD. RNA species are easily
attacked by the hydroxyl radical (OH) and several studies have
evaluated 8-hydroxyguanosine (8-OHG) as a marker of hydroxyl
radical damage to RNA (Fiala et al., 1989).
Nunomura et al. (1999) demonstrated a marked accumulation
of 8-OHG from cytoplasmic RNA using a semiquantitative
immunohistochemical analysis in the neurons of patients with
AD, particularly in vulnerable brain areas, such as the hippocam-
pus, and frontal, temporal and occipital neocortex. Neuronal 8-
OHG immunoreactivity displayed a signiﬁcant negative correlation
with the duration of the illness and the extent of Ab deposition,
thereby suggesting that RNA oxidative damage preceded patho-
logical changes in AD (Nunomura et al., 2001). The same research
team also demonstrated increased levels of 8-OHG in the frontal
cortex of subjects with familial AD, due to amutation in the PS-1 orthe APP gene (Nunomura et al., 2004). Increased 8-OHG levels of
RNA in AD brains have been conﬁrmed in other studies, in which
different assessment methods were used. Shan et al. detected that
approximately 30–70% of mRNA was oxidized in the frontal cortex
of subjects with AD, compared to 2% of the mRNA in age-matched
controls, while no differences were observed in the cerebellum
(Shan et al., 2003; Shan and Lin, 2006). Oxidation appeared not to
be a random but a selective process: of themRNA species, themost
susceptible to OSwere identiﬁed as transcripts of genes involved in
free radical modulation, detoxiﬁcation, cell death pathway, signal
transduction, synaptic plasticity, long-term potentiation, and cell
proliferation. Several oxidized mRNA coded for proteins which are
believed to be implicated in AD pathogenesis, such as PS-1,
peptides involved in free radicals regulation and detoxiﬁcation
(e.g. Cu/Zn Superoxide dismutase; Carbonyl reductase 1), cell
metabolism (e.g. Calpain), and signal transduction (e.g. MAPK
kinase 1) (Shan et al., 2003; Shan and Lin, 2006).
Ribosomal RNA (rRNA) in neurons is more abundant compared
to mRNA, and rRNA easily binds to redox-active iron, which
promotes rRNA oxidation through the Fenton reaction (Honda
et al., 2005). In hippocampal neurons from AD cases, Honda et al.
have demonstrated a signiﬁcant increase in redox active iron
which in cytoplasm was mainly associated with rRNA, thus
suggesting that redox active iron plays a pivotal role in rRNA
oxidation. Furthermore, increased levels of 8-OHG were detected
in the same cells and, of the RNA species, the greatest amount of 8-
OHG was detected in rRNA (Honda et al., 2005). Ding et al. (2005,
2006) found increased RNA oxidation in brains from AD and MCI
subjects, mainly in the superior middle temporal gyri and inferior
parietal lobule, while no alteration in 8-OHG levels was detected in
the cerebellum. Increased RNA oxidative damage mainly affected
rRNA and it was associated, both in AD and MCI, with a signiﬁcant
depletion of rRNA and RNA transfer (tRNA), impairment in
ribosome function and decreased protein synthesis. On the basis
of these results, the authors have hypothesized that an impairment
in protein production, mediated in part by OS, could promote the
onset and development of AD. Another research group investigated
RNA oxidation by assessing 8-OHG and 1-N2-propanodeoxygua-
nosine (NPrG) (an adduct formed between guanine and acrolein) in
the hippocampus and parahippocampal gyrus from amnestic MCI,
late stage AD, and control subjects. Increased levels of 8-OHG and
NPrG were demonstrated in MCI and AD parahippocampal gyrus,
compared to controls, and they were accumulated primarily in
neurons with conformational alterations of tau; the latter typically
precedes neuroﬁbrillary tangles formation. These ﬁndings,
together with the comparable intensity of RNA oxidation in MCI
and AD, led the authors to conclude that RNA oxidative damage
may be an early event in AD (Lovell and Markesbery, 2008).
Abe et al. (2002) have measured 8-OHG levels in the CSF and
serum of patients with AD, investigating their relationships with
the duration and severity of dementia. The concentration of 8-OHG
in CSF fromADpatientswas approximately ﬁvefold comparedwith
controls, and it decreased signiﬁcantly with the duration of the
illness and the progression of cognitive dysfunctions, suggesting
that RNA oxidation is an early event in AD. The level of 8-OHG in
serum was not signiﬁcantly altered in AD patients compared to
controls, and there was no correlation between CSF and serum
levels of 8-OHG in both AD cases and controls.
In conclusion and drawing on the above-mentioned studies, it
appears that 8-OHG is increased in the CNS of AD subjects, even if
RNA oxidation has not been extensively investigated in AD,
compared to other biomolecules. Post-mortem studies on AD
brains have demonstrated that RNA oxidation is more prominent
in caseswith a smaller amount of Ab plaque deposition or a shorter
duration of the disease (Nunomura et al., 2001, 2004; Abe et al.,
2002); 8-OHG accumulation is more marked in hippocampal
F. Mangialasche et al. / Ageing Research Reviews 8 (2009) 285–305294neurons free of NFT, compared to neurons with NFT (Nunomura
et al., 1999, 2001). Furthermore, 8-OHG is increased in MCI brains,
which, at least in part, represent a prodromal stage of AD (Ding
et al., 2006; Lovell and Markesbery, 2008). All this data point to 8-
OHG as an effective candidate as a biomarker of early AD, or a
marker predicting conversion from a prodromal stage to an early
stage of AD (Nunomura et al., 2006a).
6. Proteins
Within proteins, all amino acids can be attacked by ROS and
RNS, but sulphur-containing and aromatic amino acids are the
most susceptible (Stadtman and Levine, 2003). The oxidation of
amino acids leads mainly to the formation of carbonyl derivates,
while peroxynitrite (ONOO) can nitrate tyrosine groups of
proteins and form the stable compound 3-nitrotyrosine. Another
product of protein oxidation is dityrosine. Intracellular proteins
might also be oxidatively modiﬁed via secondary mechanisms
resulting from the reactions of free radicals with other cellular
constituents, such as lipids, carbohydrates, and nucleic acids
(Breusing and Grune, 2008). In addition to the side chain
modiﬁcations, protein fragmentation and protein cross-linking
can also occur. Furthermore, protein oxidation can give rise to
other radical species, which can cause damage to other biomo-
lecules. Unlike DNA oxidation products, oxidized amino acids are
rarely repaired: mildly oxidized proteins are usually degraded by
the 20S proteasome, an intracellular protease present in all cells of
the CNS. It is responsible for the degradation of oxidized,
aggregated, and misfolded proteins, thus playing an important
role in maintaining neuronal homeostasis (Voss and Grune, 2007).
Only the easily oxidizable amino acids, cysteine and methionine,
can be reduced to the initial form, and their repair is promoted by
different enzymes, including the thioredoxin/thioredoxin reduc-
tase system and methionine sulphoxide reductase (Breusing and
Grune, 2008).
Speciﬁcally, it has been suggested that methionine acts as an
antioxidant in proteins and peptides, such as Ab, by scavenging
oxidizing species and forming methionine sulphoxide (Hou et al.,
2002). This oxidized amino acid is speciﬁcally reduced to its native
form by methionine sulphoxide reductase (Stadtman et al., 2003).
However, this enzyme activity has been reported to decline in the
superior and middle temporal gyri and hippocampus of patients
with AD, resulting in a loss of antioxidant defence and increase in
oxidized methionine residues (Gabbita et al., 1999). Cysteine
sulfhydryl groups can be generated from disulﬁdes by cellular
reducing agents, such as GSH and protein disulﬁde isomerase, that
reverse the formation of non-native disulﬁde bridges (Laboissiere
et al., 1995). Furthermore, it has been suggested that nitrotyrosine
may be repaired by a denitrase enzyme, although this has not been
substantiated (Irie et al., 2003). Protein oxidation/nitration results
in functional disruption and the cross-linking of proteins by
oxidative processes may lead to resistance to intracellular and
extracellular removal, even though damaged peptides are exten-
sively ubiquinated. Carbohydrates and oxidized lipids are able to
react with oxidized proteins contributing to the process of protein
aggregation and inhibiting proteasome degradation (Friguet and
Szweda, 1997; Shringarpure et al., 2000; Breusing and Grune,
2008).
Several studies have shown that proteasome activity is
impaired in AD and MCI. It has been also demonstrated that
proteasome oxidative modiﬁcations are increased in AD, and this
could contribute to reducing proteasome ability to clearance
intracellular protein aggregates (Ding and Keller, 2001; Song and
Jung, 2004; Cecarini et al., 2007). Therefore, the accumulation of
oxidized/nitrated proteins in AD is a probable consequence of
imbalance in any one of a number of different systems, includingfree radical generation, antioxidant defences or the efﬁciency of
oxidized/nitrated protein repair or removal.
The use of proteins as markers of oxidative/nitrosative stress
can offer several advantages as compared with measuring lipid
peroxidation or the oxidative basemodiﬁcation of DNA. This is due
to the following reasons: (i) proteins play a key role in maintaining
cellular structure and functions, thus alterations of the protein
structure due to OS/NSmay be reﬂected at functional level, and the
change of activity can be assayed; (ii) the products of oxidative/
nitrosative modiﬁcations of proteins are relatively stable; and (iii)
sensitive assays are available for their detection (Chakravarti and
Chakravarti, 2007).
Protein carbonyls have been assessed in several investigations.
They increase exponentially with age and have been shown to play
a role in the pathophysiology of AD. Protein carbonyls may be
generated by backbone fragmentation, hydrogen atom extraction
at a carbon or an attack on several amino acid side-chains, and by
the formation of adducts between some amino acid residues and
the products of lipid peroxidation. Protein carbonyls are also
produced by glycation/glycoxidation of lysine amino groups,
which end with the synthesis of ‘‘advanced glycation end
products’’ (AGEs) (Sultana et al., 2006d). Protein carbonyls can
be detected with 2,4-dinitrophenylhydrazine (DNPH), and it
appears that most of the DNPH-detectable carbonyls found on
proteins result from modiﬁcation by bi-functional reactive
aldehyde products of lipid and sugar oxidation.
Most of the studies conducted in the aging brain have
concluded that oxidized proteins do accumulate with age. In a
study by Smith et al. (1991) the amount of protein oxidation was
measured by a general DNPH assay. The results revealed a general
logarithmic increase in protein damage with age in the human
cerebral cortex, and no signiﬁcant differences were observed
between controls and subjects with AD. In this study not only
protein carbonyls levels, but also the activities of creatine kinase
and glutamine synthase weremeasured in the frontal and occipital
lobe regions as a function of age. While protein carbonyl content
increased with age, the activities of creatine kinase and glutamine
synthase decreased, and glutamine synthase activity appeared to
be selectively lost in AD brains compared with age-matched
controls. In a later study, Aksenova et al. (1999) demonstrated a
signiﬁcant increase in protein carbonyl content in the frontal
cortex of subjects with AD; protein carbonyls levels were
negatively correlated with creatine kinase activity, which was
lower in AD than in controls.
Hensley et al. (1995) evaluated the content of four biomarkers
of neuronal protein oxidation, including DNPH-reactive protein
carbonyls, in three brain regions (the cerebellum, inferior parietal
lobule and hippocampus) of AD and age-matched control subjects.
Protein carbonyls were signiﬁcantly increased in both the
hippocampus and the inferior parietal lobule, but unchanged in
the cerebellum, a ﬁnding which is consistent with the regional
pattern of histopathology of AD. Similar results have been found by
Lyras et al. (1997), who assessed protein carbonyls in different
brain regions of AD subjects and controls. Overall, samples levels of
protein carbonyls in AD tended to be increased in the frontal,
occipital, parietal, and temporal lobes, middle temporal gyrus, and
hippocampus, but a signiﬁcant difference was found only in the
parietal lobe. In another study, increased levels of protein
carbonyls were detected in the superior and middle temporal
gyri in patients with early-stage AD and MCI compared with
normal control subjects, while no signiﬁcant alteration in protein
carbonyl content was detected in the cerebellum of both early AD
and MCI subjects, in comparison with controls (Keller et al., 2005).
Pamplona et al. have used GC–MS to analyze the presence of
glutamic semialdehyde, which is derived from the metal-catalyzed
oxidation of proline and arginine, and aminoadipic semialdehyde, in
F. Mangialasche et al. / Ageing Research Reviews 8 (2009) 285–305 295turn resulting from lysine oxidation, in the frontal cerebral cortex
of brains from AD subjects. Both biomarkers were signiﬁcantly
higher in AD samples than in age-matched controls and the author
also demonstrated increased levels of other biomarkers of protein
oxidation. The latter include MDA-adducts, which are considered
lipoxidation products, and carboxyethyl-lysine/carboxymethyl-
lysine, which have been termed mixed AGEs-advanced lipoxidation
products (Pamplona et al., 2005). CRA, generated during lipid
peroxidation, is highly reactive and it promotes protein carbonyla-
tion. One study showed an increased presence of CRA-protein
adducts in the hippocampus of AD subjects, compared to age-
matched controls, which were preferentially localized in reactive
glial cells (Kawaguchi-Niida et al., 2006).
Ortho-tyrosine is another index of protein oxidation, formed by
a hydroxyl radical reaction with tyrosine. It has been investigated
in AD brain, but no difference in the level of ortho-tyrosine was
found in the frontal cortex from AD, compared to controls (Hayn
et al., 1996). Peroxynitrite is a source of hydroxyl radical-like
reactivity that directly oxidizes proteins, with resultant carbonyls
formation from the side-chain and peptide-bond cleavage.
Peroxynitrite also causes the nitration of tyrosine residues, thus
forming 3-nitrotyrosine (3-NT), which can be used as an index of
peroxynitrite action (Crow and Beckman, 1995). Tyrosine nitration
has been shown to alter protein functioning, with a change in
catalytic activity, cell signalling, and cytoskeletal organization
(Schopfer et al., 2003); 3-NT proteins cannot be phosphorylated by
tyrosine kinases (Martin et al., 1990). Subsequently, signal
transduction mediated by tyrosine kinases – such as trophic
factors, nerve growth factors and brain-derived neurotrophic
factors – is disturbed and cell apoptosis may occur. In two reports
increased 3-NT was detected in the neuronal cytoplasm of AD
brains, both in cells containingNFT and in those lackingNFT (Smith
et al., 1997b; Su et al., 1997). In these studies nitrotyrosine
immunoreactivity was increased in regions of the cerebral cortex
affected by neurodegeneration, whereas it was undetectable in the
same brain regions of controls. The distribution of nitrotyrosine
was essentially identical to the distribution of free carbonyls
(Smith et al., 1996).
Data obtained by immunoprecipitation analysis has shown a
signiﬁcant increased level of carbonylation and nitration of the
proapoptotic protein p53 in the AD brain. A higher degree of
carbonylation of p53 was observed also in the MCI brain, in
comparison to controls. The authors also found higher p53 levels
in the AD and MCI brain, and increased p53 oxidation by the
lipid peroxidation product HNE (Cenini et al., 2008b). p53 plays
a key role in oxidative-dependent apoptosis and neuronal death,
thus p53 oxidative/nitrosative modiﬁcations could be involved
in the neuronal loss observed in AD and MCI (Cenini et al.,
2008a). This hyphotesis has been reinforced by recent ﬁndings
from the same research group, showing increased levels of the
monomeric and dimeric form of p53 in the AD brain; patients
having increased brain level of p53 showed higher level of S-
glutathionylation of both p53 monomer and dimer, compared to
controls (Di Domenico et al., 2009). Proteins associated with
neurodegeneration which are redox regulated through S-
glutathionylation have been also showed to be signiﬁcantly
more S-glutathionylated in the brain of subjects with AD, in
comparison to controls (Newman et al., 2007). GSH is one of the
most important antioxidant in the brain, and S-glutathionyla-
tion is a reversible post-translational modiﬁcation due to GSH
reversible binding to protein thiol groups. The role of S-
glutathionylation has not been completely clariﬁed, but it
seems that this process plays a critical role in sulfhydryl
homeostasis and signal transduction. Some studies report S-
glutathionylation as a protective mechanisms against perma-
nent oxidative damage of protein, while others describe the roleof this post-translational modiﬁcation in modulating protein
functioning. Protein S-glutathionylation increases under condi-
tion of oxidative stress, thus contributing to the disturbance of
normal cell signalling and potentially promoting neurodegen-
eration (Mieyal et al., 2008).
Biomarkes of protein oxidative and nitrosative damage have
been searched for not only in the brain, but also in CSF. Deploying
sensitive HPLC methods, Hensley et al., have demonstrated that 3-
NT and dityrosine levels were ﬁve to eight fold higher in the
hippocampus, neocortex and ventricular CSF of patients with AD,
when compared with cognitively normal controls (Hensley et al.,
1998). 3-NT concentration and 3-NT/tyrosine ratio were increased
six-fold in the lumbar CSF of AD compared with controls of similar
age, and both parameters were raised signiﬁcantlywith decreasing
cognitive functions (Tohgi et al., 1999). These results were not
conﬁrmed when the GC–MS/MS method was applied to analyzing
human CSF. Indeed, the investigators demonstrated that the
concentration of free 3-NT CSF was considerably lower than that
previously reported, and only a few subjects with AD showed
increased levels, while the majority of patients had 3-NT levels in
the same range as the controls (Ryberg et al., 2004). Any
discrepancy between these results is probably due to different
methods of sample preparation and analysis. Furthermore, human
CSF contains free tyrosine, nitrites and nitrates, thus the in vitro
production of 3-NT in CSF samples is possible; regarding HPLC and
MS techniques, the results may be altered by the artiﬁcial
formation of 3-NT.
More recently, the concentration of 3-NT, carboxymethyl-
lysine and the oxidized tryptophan moiety, N-formyl kynurenine,
were found to be signiﬁcantly elevated in CSF from AD, where the
Mini Mental State Examination (MMSE) score revealed an inverse
correlation with 3-NT levels. Moreover, after removal of the CSF
proteins bymeans of ultra-ﬁltration techniques, increased levels of
free 3-NT were detected, indicating that the degradation of
nitrated proteins had occurred (Ahmed et al., 2005).
Protein oxidative and nitrosative damage has also been
explored in peripheral tissues. Polidori et al. (2004) have evaluated
the carbonyl and dityrosine content in plasma immunoglobulins
from patients with AD and control subjects. Immunoglobulin
levels of dityrosine but not of carbonyls were shown to be
signiﬁcantly higher in AD as compared to controls, in contrast to a
previous report of an increased total amount of oxidatively
modiﬁed proteins (Conrad et al., 2000); no signiﬁcant difference in
total plasma carbonyls between AD and normal subjects has been
identiﬁed by other researchers (McGrath et al., 2001; Baldeiras
et al., 2008). Calabrese et al. (2006) have demonstrated increased
levels of OS and NS in AD subjects in plasma and peripheral
lymphocytes, detecting higher levels of protein carbonyls, 3-NT
and HNE in AD plasma and lymphocytes, compared to controls.
Interestingly, these values were related to decreased levels in the
free radical scavenger GSH, an increased level of its oxidized
moiety, disulﬁde oxidized glutathione (GSSG), and lower levels of
the GSH/GSSG ratio in lymphocytes from AD patients, in
comparison to controls. In lymphocytes from AD there was
observed an increased expression of stress-induced proteins, such
as the heat shock proteins (HSPs) Hsp72 and Hsp60. Furthermore,
the enzymes heme oxygenase (HO-1) and thioredoxin reductase
(TRXr), which, have been shown to play a critical role in protecting
against oxidative injury, were increased in AD plasma and
lymphocytes, in comparison with controls. Similar ﬁndings have
also been described in another recent study, showing increased
plasma concentrations of protein carbonyls in AD and amnestic
MCI patients, in comparison with cognitively normal subjects. The
degree of protein oxidation was comparable in MCI and AD, and in
both groups the GSH/GSSG ratio was signiﬁcantly decreased,
compared to controls (Bermejo et al., 2008).
F. Mangialasche et al. / Ageing Research Reviews 8 (2009) 285–305296The oxidative inactivation of enzymes is another index of
oxidative damage to proteins, and indeed various studies have
demonstrated that glutamine synthase and creatine kinase
activities decrease with age and do so more markedly in the AD
brain (Smith et al., 1991; Aksenova et al., 1999). Sohal and co-
workers, who had initially veriﬁed that protein carbonyl content
in houseﬂies was associated with life expectancy, also found
that in the same model mitochondrial aconitase, an enzyme
involved in the citric acid cycle, is a speciﬁc target of OS together
with age (Sohal et al., 1993; Yan et al., 1997). The oxidative
damage was paralleled by a loss in the catalytic activity of
aconitase, which contains an iron-sulphur cluster, thereby
rendering it very susceptible to oxidative stress. While the
potential serious implications of an impaired activity of
aconitase have been elegantly summarized (Shadel, 2005), we
recently observed that aconitase activity decreases in lympho-
cytes and puriﬁed mitochondria from AD compared to controls
(Mecocci et al., unpublished data). This is of interest not only in
light of the possibility of peripherally assessing aconitase as a
biomarker of oxidative stress in AD, but also because the decline
of aconitase activity in patients with AD markedly resembles
that of aconitase activity in subjects with MCI, thus suggesting
that mitochondrial dysfunction and oxidative stress have
chronological primacy in AD.
A further step in understanding the relationship between the
oxidative/nitroxidative modiﬁcations of proteins, their func-
tional impairment, and neuronal death in AD has been made by
means of the redox proteomic analysis. Protein oxidation/
nitroxidation appears not to be a random process but rather it
involves speciﬁc proteins, which could be more susceptible
because of sequence motifs, environmentally-exposed residues,
bound ligands, and interactions with redox-metal group.
Proteomic approach is an emerging method for the identiﬁca-
tion of proteins, possibly allowing the screening of a subset of
peptides within the brain proteome, which might reﬂect the
extent of OS/NS in AD. The use of proteomics to speciﬁcally
identify ROS/RNS-modiﬁed proteins in the AD brain permits the
determination of which peptides are more affected by oxidation
and nitration, providing insights into the potential mechanisms
of neurodegeneration. Redox proteomics has been used by
different laboratories to detect and identify carbonylated and
nitrated proteins in the AD brain, and for several peptides there
is evidence that they may play an important role in neurode-
generation (Castegna et al., 2002a,b, 2003; Butterﬁeld, 2004;
Korolainen et al., 2006; Sultana et al., 2006a,b,c,e).
Butterﬁeld et al. performed the ﬁrst proteomic analysis in
detecting protein oxidative damage on AD brains, by identifying
threemain targets of protein carbonylation: creatine kinase BB (CK
BB), ubiquitin carboxy-terminal hydrolase L-1 (UCH L-1), and
glutamine synthetase (GS) (Castegna et al., 2002a). Thereafter,
many studies from the same laboratory and other research groups
identiﬁed different proteins [a-enolase, g-enolase, b-actin, lactate
dehydrogenase (LDH), triose phosphate isomerase (TPI), carbonic
anhydrase II (CAH II), g-soluble N-ethylmaleimide-sensitive
factor-attachment protein (g-SNAP), neuropolypeptide h3, phos-
phoglycerate mutase 1 (PGM1), dihydropyrimidinase related
protein-2 (DRP-2), glutamate transporter-1 (GLUT-1), heat shock
cognate 71 (HSC 71), peptidyl prolyl cis–trans isomerase (Pin 1),
glutathione-S-transferase, neuroﬁlament protein L,a-tubulin, glial
ﬁbrillary acidic protein], which were oxidized and functionally
impaired in AD brains, further supporting the hypothesis of
oxidative stress as a mediator of synaptic loss and a presumed
factor in the formation of tangles and plaques (Lauderback et al.,
2001; Castegna et al., 2002a,b; Choi et al., 2004; Pamplona et al.,
2005; Sultana et al., 2006a; Sultana et al., 2006b; Butterﬁeld and
Sultana, 2007).Deploying a redox proteomics approach, Butterﬁeld et al.
observed in the AD brain the nitration of speciﬁc proteins: a-
enolase, g-enolase, L-LDH, triose phosphate isomerase, glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH), ATP synthase a
chain, voltage-dependent anion channel protein-1 (VDAC-1), and
carbonic anhydrase II. These results support the role of protein
nitration in promoting the perturbations, observed in AD, of
mitochondrial functions, energy metabolism and pH regulation
(Castegna et al., 2003; Sultana et al., 2006e). UCH L-1, one of the
components of the proteosomal pathway, was found to be
oxidized and dysfunctional in the inferior parietal lobule and
hippocampus of AD subjects (Castegna et al., 2002a), and this
could be one of the reasons for the observed increase in the
nitrated proteins associated with this disorder. A proteomic
analysis allowed Butterﬁeld’s research group to identify deox-
yhemoglobin, a-crystallin B, GAPDH, and a-enolase as targets of
increased S-glutathionylation in the brain of patients with AD, in
comparison to age-matched controls. GAPDH anda-enolasewere
also shown to have reduced activity in the AD brain, with possible
negative implications for brain glucose metabolism (Newman
et al., 2007).
Increased levels of protein carbonyls and HNE-modiﬁed
proteins were detected in the hippocampus of subjects with
amnestic MCI, which is considered a transition between normal
aging and AD. Using proteomic analysis, it has been shown that
protein oxidation concerned mainly energy-related enzymes (a-
enolase, pyruvate kinase M2), proteins involved in neurotransmis-
sion (glutamine synthetase), in the cell cycle and in tau
phosphorylation (Pin 1). The oxidized proteins also displayed
decreased activity in MCI, when compared to controls, and since
those peptides are important in cell metabolism, synaptic
plasticity and mitogenesis/proliferation, their oxidative inhibition
could play a key role in the development of AD (Butterﬁeld et al.,
2006a; Reed et al., 2008). It was also observed in theMCI brain that
protein nitration was 25% higher in the inferior parietal lobule and
41% higher in the hippocampus, in comparison to the same brain
regions from control subjects (Butterﬁeld et al., 2007). Few
investigations have been published regarding on the proteomic
analysis in the peripheral tissues of patients with AD: one study
found that a-1-antitrypsin and ﬁbrinogen g-chain precursor
proteins exhibited a two-six fold speciﬁc oxidation index in
plasma from AD subjects when compared to controls, and both
these proteins have been suggested to be involved in AD
pathophysiology (Choi et al., 2002).
In conclusion, redox proteomics studies have identiﬁed several
damaged proteins in AD and MCI. These proteins deal with energy
metabolism, glutamate reuptake, the recycling of damaged or
aggregated proteins through the proteasome, the maintenance of
membrane structure and function and directing dendrites to
adjacent neurons. All these functions are compromised in AD and
proteomic analysis has identiﬁed peptides whose decreased
function is consistent with the pathophysiology of AD, thereby
providing new insights into the potential mechanisms of
neurodegeneration in this disorder. Speciﬁcally, data from
proteomic studies support the notion that protein carbonylation
and nitration alter energy metabolism, pH regulation, and
mitochondrial functions. The imbalance of these processes could
promote the onset of AD and its progression. Furthermore,
modiﬁed proteins identiﬁed by proteomics could be a diagnostic
and prognostic marker of the disease. The proteomic-mediated
identiﬁcation of oxidized/nitrosylated peptides in theMCI brains is
ongoing in several studieswhich could assist the discovery of novel
biomarkers of AD-related neurodegeneration. Thus, mechanisms
of disease progression would be clariﬁed, thereby providing
insights into the development of pharmacological strategies in
preventing the conversion from MCI to AD.
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Alzheimer’s disease?
The mechanisms responsible for the selective dysfunction and
neuronal death in the AD brain remain unclear. Aging is the major
risk factor for AD, and, since it has been largely proved that an
elevation in oxidative/nitrosative damage is one of the most
ubiquitous alterations observed in aging cells and tissues, it is
likely that increased OS/NS contributes to the development of age-
related disorders, such as AD. However, it has not been totally
clariﬁed whether the increased oxidative/nitrosative damage in
MCI and AD subjects constitutes an acceleration of the ‘‘normal’’
age related raise in oxidative/nitrosative injury, or whether
alternative pathways of ROS/RNS production are responsible for
the increased levels of OS/NS, which are observed in MCI and AD
subjects (Ding et al., 2007).
Several sources/conditions causing ROS/RNS hyperproduction
have been suggested as playing a role in AD pathogenesis (Zhu
et al., 2007b):
(i) The loss of metal homeostasis, with a subsequent accumula-
tion of iron and/or copper in the brain (Lovell et al., 1998;
Crouch et al., 2007), which catalyzes the formation of OH from
H2O2, as well as the synthesis of AGEs. The latter, in the
presence of transition metals, can undergo redox cycling with
consequent ROS production (Yan et al., 1994, 1995). Further-
more, AGEs and Ab activate speciﬁc receptors, such as that for
advanced glycation end products (RAGE) and the class A
scavenger-receptor, which increase ROS production (El
Khoury et al., 1996; Yan et al., 1996).
(ii) Activated microglia/astrocytes, such as those surrounding
most senile plaques (Cras et al., 1990), are a source of NO and
O2
 (Colton and Gilbert, 1987) and they can react to form
peroxynitrite.
(iii) Impairment in mitochondrial metabolism, and subsequent
deﬁciency in key enzyme functions. Mitochondrial dysfunc-
tion, due in part to damage of the mitochondrial genome, can
increase free radical production, suggesting that these
organelles may be the major and possible initiating source
of ROS (Davis et al., 1997; Castellani et al., 2002; Moreira et al.,
2008).
(iv) Dysfunction in cellular proteolysis, including altered lysoso-
mal functions and proteasome inhibition, induces protein
oxidation and impairs the activity of mitochondrial complexes
I and II, thus increasing ROS production (Zhu et al., 2007b).
(v) Ab itself has been directly implicated in ROS formation
through peptidyl radicals (Hensley et al., 1994; Sayre et al.,
1997a). Speciﬁcally, Ab oligomers seem to bemore efﬁcient in
promotingOS, compared to the ﬁbrilized form of Ab (Tamagno
et al., 2006). APP and Ab can be detected in mitochondrial
membranes, where they can damage the electron-transport
chain, promote mitochondria dysfunction and increase ROS
production (Reddy and Beal, 2008). In addition to the direct
induction of oxidative stress, Ab can also indirectly generate
an oxidative microenvironment, for example, via the stimula-
tion of a local immune response. Indeed, the cellular and
soluble mediators of inﬂammation have been identiﬁed in
post-mortem AD tissues (McGeer et al., 2000). Oxidative
damage may, in turn, play a role in the amyloid deposition
observed in AD; the complex reciprocal relationships between
Ab deposition, excitotoxicity, calcium dysregulation and ROS
production in AD have been elegantly summarized (Barnham
et al., 2004; Mattson, 2004; Valko et al., 2007). A recent
hypothesis which considers Ab production as a protective
consequence to an underlying disease mechanism merits
consideration: it views the known lesions of AD as acompensatory response which is adaptive and protective
(Joseph et al., 2001; Lee et al., 2004). Indeed, Ab possesses
many physiological roles, including redox-active metal
sequestration (Smith et al., 1997a) and superoxide dismutase
(SOD)-like activity (Curtain et al., 2001). Furthermore, it has
been shown to be inversely correlated with oxidative stress
markers (Nunomura et al., 2001), thereby suggesting that it
may have antioxidant effects. It has been proposed that
oxidative damage could elicit compensatory mechanisms,
such as Ab deposition and hyperphosphorylated tau, in an
attempt to restore the redox balance thereby avoiding
neuronal death. However, the antioxidant activity of both
agents evolves into a pro-oxidant during the progression of the
disease, representing a ‘‘gain-of-function’’ transformation,
which can result in an increase in free radical production
and a decrease in clearance mechanisms (Zhu et al., 2007b).
Not only free radical hyperproduction, but also an impaired
response to oxidative and nitrosative injury may predispose to an
accumulation of oxidative and nitrosative damage in AD. Rinaldi
et al. (2003) have evaluated the peripheral levels and activities of a
broad spectrum of non-enzymatic and enzymatic antioxidants in
elderly subjects with MCI and AD, in comparison with controls.
MCI and AD subjects displayed a similar depletion in non-
enzymatic antioxidants (Vitamin A, Vitamin C, Vitamin E, uric
acid and carotenoids) and the in activities of plasma and
erythrocyte SOD, in addition to plasma GPx, when compared to
controls. These ﬁndings suggest that subjects developing MCI and
AD may have an antioxidant network which is inadequate at
counteracting the hyper-production of free radicals during a
recently established condition of oxidative stress.
Several other studies have conﬁrmed decreased levels of non-
enzymatic antioxidants in subjects with AD (Bourdel-Marchasson
et al., 2001; Mecocci et al., 2002; Glaso et al., 2004; Polidori et al.,
2004; Pratico` and Sung, 2004), while the overall data regarding
levels of enzymatic antioxidants in plasma and/or CNS in AD
remain conﬂicting. Indeed, while some investigations have
demonstrated a decreased level in the activity of enzymatic
antioxidants in AD patients (Pappolla et al., 1992; Marcus et al.,
1998; Ihara et al., 2000; Rinaldi et al., 2003; Casado et al., 2008),
others did not conﬁrm these ﬁndings. This fact either revealed no
differences (Bourdel-Marchasson et al., 2001) or increased levels of
enzymes, such as GPx, SOD, glutathione reductase, and Cat, which
in turn suggest a compensatory rise in antioxidant activity in
response to increased free radical formation (Balazs and Leon,
1994; Lovell et al., 1995; Repetto et al., 1999; Serra et al., 2001;
Schuessel et al., 2004; Martin-Aragon et al., 2009). A recent study
has demonstrated an alteration in the levels and activity of several
antioxidant enzymes in the MCI brain, compared to age-matched
controls, suggesting that MCI subjects could have an inadequate
antioxidant enzymatic activity, that might contribute to oxidative
damage accumulation (Sultana et al., 2008).
Whilst there is a large body of evidence pointing to higher levels
of OS and NS in AD in CNS and in peripheral tissues, it is not yet
clear whether the increase in oxidative/nitrosative damage in the
AD brain plays a role in promoting AD pathogenesis or whether
these phenomena are simply by-products of neurodegeneration. It
is conceivable that OS/NS are both early, ‘‘upstream’’, events which
contribute to AD pathogenesis but they could also be secondary,
‘‘downstream’’, consequences of other pathogenetic mechanisms,
which amplify oxidative/nitrosative damage, thus generating a
vicious circle promoting neurodegeneration (Sayre et al., 2008).
Several considerations allow us to consider OS/NS as key factors
in AD pathogenesis: primarily, not only age, but also other risk
factors for AD are able to promote alterations in the redox
homeostasis, including apolipoprotein E genotype (Miyata and
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mutations (Cecchi et al., 2002; Rottkamp et al., 2002; Marques
et al., 2003; Li et al., 2004). The temporal and spatial occurrence of
oxidative/nitrosative injury are also important in supporting
causal relationship of neurodegeneration in AD. Indeed, growing
evidence suggests that OS/NS occur before the onset of symptoms,
and that oxidative/nitrosative changesmainly accumulate in those
cerebral regions vulnerable to AD pathology, while areas like the
cerebellum, usually spared in AD, display levels of OS/NSwhich are
similar to age-matched controls. An accumulation of markers of
OS/NS appears to precede the formation of senile plaques, possibly
independent of NFT accumulation (Zhu et al., 2000; Nunomura
et al., 2001; Pratico` et al., 2001; Gomez-Ramos et al., 2003);
increasing evidence for the potential pathogenetic role of soluble
Ab oligomers rather than Ab ﬁbrils merits further research to
assess the temporal relationship between OS/NS and formation/
release of soluble Ab oligomers (Zhu et al., 2007a).
More recently, multiple studies have demonstrated that lipid
peroxidation, protein oxidation/nitrosylation, and nucleic acid
oxidation occur in MCI subjects, in the same selected brain regions
damaged in AD and, as with AD, they can also be detected in
peripheral tissues. In the numerous studies summarized in this
paper, the degree of OS/NS was comparable between AD and MCI
subjects, and, since MCI may represent a prodromal stage of AD,
these ﬁndings support the functional importance of an oxidative/
nitrosative imbalance as an early crucial event in mediating AD
pathogenesis.
The evidence that higher antioxidant plasma levels are
associated with improved cognitive functions and a lower risk
of developing dementia/AD further supports a pathogenetic role of
OS/NS in AD. Several clinical and epidemiological studies regarding
healthy adults/elderly subjects demonstrated a positive correla-
tion between various circulating antioxidants and cognitive
performance, and an inverse relationship with the risk of
developing dementia/AD (Gale et al., 1996; La Rue et al., 1997;
Perrig et al., 1997; Riviere et al., 1998; Schmidt et al., 1998; Berr
et al., 2000; Helmer et al., 2003; Cherubini et al., 2005). Mecocci
et al. (2000) have detected high levels of vitamin A and vitamin E in
the plasma of mentally healthy centenarians, thereby suggesting a
protective role of these micronutrients in the oldest old.
How could increased oxidative/nitrosative damage promote
cellular dysfunction and neurodegeneration? The nature of the
relationship between OS/NS and cell death has not yet been
completely elucidated but it is clear that a controlled production of
ROS and RNS is important in cell activation, proliferation or
programmed cell death. A redox imbalance represents a regulatory
sensor for several nuclear transcription factors, and there is
increasing evidence that ROS and RNS are important mediators of
signal transduction via several pathways. However, under
pathological conditions abnormally large concentrations of ROS/
RNS may lead to permanent changes in signal transduction and
gene expression (thus impairing cell metabolism and homeostasis)
and contribute to cell failure in adapting to stressful stimuli or even
surviving (Polidori et al., 2007; Valko et al., 2007). The ability of
oxidative/nitrosative damage in promoting toxicity probably relies
on the capacity of oxidative/nitrosativemodiﬁcations to impair the
function of a given macromolecule, or alternatively promote a
potentially deleterious gain of function event for a speciﬁc
macromolecule (Ding et al., 2007).
Many products of OS/NS, regardless of whether they represent
causes or consequences of tissue injury, have the potential for
promoting neurodegeneration. Several human, animal, and in vitro
studies have implicated products of lipid peroxidation in the
pathogenesis of neuronal degeneration in AD (Keller and Mattson,
1998; Mattson, 1998; Markesbery and Carney, 1999; Cenini et al.,
2008b; Valko et al., 2007; LoPachin et al., 2008). Nucleic acidoxidation is also important since the oxidative modiﬁcations of
RNA, nDNA and mtDNA are thought to play a key role in the
selective neuronal loss associated with mammalian aging and
neurodegeneration (Nunomura et al., 1999; Lu et al., 2004; Melov,
2004; Beal, 2005). Speciﬁcally, there is evidence that RNA
oxidation is not a harmless epiphenomenon, but it may be directly
associated with neuronal deterioration (Shan et al., 2003, 2007).
Finally, different studies have demonstrated how protein oxida-
tive/nitrosative damage, especially if associated with impaired
protein synthesis and the altered removal of injured peptides, can
have deleterious consequences for the cell: it can promote
metabolism dysregulation and increase ROS/RNS production, thus
being an important step in progressive neuronal injury, leading to
clinically-evident disease (Butterﬁeld and Sultana, 2007; Ding
et al., 2007; Polidori et al., 2007).
As it is not yet clear what category of biomolecules is ﬁrst
affected by OS/NS in the course of AD, studies regarding the
temporal proﬁle of biomolecule oxidative/nitrosative modiﬁca-
tions are, therefore, required, to clarify which class of molecule is
initially damaged, and how this may inﬂuence themetabolism and
activity of other cellular macromolecules.
Another important question is why only certain neuronal
populations are affected by the disease. A model of multi-step
pathogenesis, the so-called ‘‘two-hits hypothesis’’, considers AD as
result of serial insults that alone are insufﬁcient to cause the
disease, but when they occur together in the same cell, they are
able to promote the degenerative process (Zhu et al., 2004). Based
on an analysis of oxidative stress signalling and mitotic signalling
pathways in vulnerable neuronal populations in AD, it has been
hypothesized that both oxidative stress and aberrant mitotic
stimuli can independently initiate AD neurodegeneration, but both
are necessary in propagating AD pathogenesis and progression
(Zhu et al., 2007a). Accordingly, whilst they may not constitute
primary initiating events, oxidative/nitrosative stress is an early
phenomenon associated with neurodegeneration. It is required for
the propagation of an integrated series of cellular events, including
excitotoxic stimulation, the dysfunction of critical proteins, and
loss of metal homeostasis, all contributing to neuronal death. A
shift from redox regulation to a condition of oxidative/nitrosative
stress could, therefore, play a key role in AD pathogenesis as OS/NS
could be main actor in a cycle of events leading to neurodegenera-
tion; inhibiting OS and NS could break this cycle (Andersen, 2004;
Sayre et al., 2008).
Studies involving MCI subjects may provide an opportunity for
clarifyingwhat speciﬁc neurochemical alterations are important in
initiating AD pathogenesis, and which are secondary phenomena.
The study of MCI can assist us in explaining the role of many of the
pathways which could contribute to ROS/RNS hyperproduction in
MCI and AD, bearing in mind that these sources of free radicals
interact with each other in a complex manner, and most sources
have a positive feedback (Zhu et al., 2007b).
8. Conclusions
While AD affects patients later in life, abundant evidence
suggests the existence of a ‘‘preclinical’’ stage, commencing years
before the clinical diagnosis,whenan individual appears cognitively
normal while he/she is undergoing extensive pathological changes
in the brain. Biomarkers should serve as early diagnostic indicators
or as markers of preclinical pathological change. Regarding the
development and implementation of neuroprotective and disease-
modifying therapies, the presence of robust biomarkers will be
fundamental in screening for an increased susceptibility toAD, as an
aid to diagnosis, identifying subsets of patients who are more
responsive to treatment, andobjectivelymonitoring theprogression
and response to treatments.
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reﬂect a neuropathological characteristic of AD. It should be
validated in patients with a neuropathological diagnosis (Grow-
don, 1998; Frank et al., 2003) and several large-scale studies are
on-going in different countries to develop and validate these
markers. Biomarkers of OS/NS could have an important impact on
the ability to test hypotheses concerning oxidative/nitrosative
damage in AD pathogenesis. The key role of OS/NS in AD implies
that biomarkers for oxidative/nitrosative damage could become an
expression of risk factors for AD since they are effectively an
indirect index of ROS/RNS levels, albeit more difﬁcult to quantify.
The primacy of OS/NS in AD pathogenesis implies that therapeutic
strategies aiming at decreasing the level of oxidative/nitrosative
damage are one of themain routes to preventing the onset of AD or
delay its progression. In this regard, it is necessary to identify the
reason for the lack of convincing, beneﬁcial effects of antioxidant
therapies in lowering the incidence of AD or delaying the
progression of the disease (Sano et al., 1997; Morris et al., 1998;
Luchsinger et al., 2003; Zandi et al., 2004; Fillenbaum et al., 2005;
Maxwell et al., 2005; Petersen et al., 2005).
The inﬂuence that ROS and RNS has in modulating many
different signalling pathways might explain the limited efﬁcacy of
antioxidant supplements in preventing or treating AD, although it
cannot be excluded that this is due instead to the use of high doses
of a single antioxidant. Indeed, epidemiological studies regarding
the dietary intake of antioxidants revealed a higher efﬁcacy than
antioxidant supplements in preventing AD, thereby suggesting
that the antioxidant mixture contained in food is more effective
(Engelhart et al., 2002; Morris et al., 2002; Laurin et al., 2004)
(other studies did not conﬁrm these ﬁndings (Laurin et al., 2004)).
It is also important to note that all clinical trials regarding
antioxidants to date share a common weakness, such as the
monitoring of drug circulating levels and/or markers for monitor-
ing the ability of an in-vivo drug to reducing the magnitude of
oxidative and nitrosative damage (Pratico`, 2008). Indeed, a central
issue to be addressed in the ﬁeld of the oxidant/antioxidant
balance of the organism in AD and the evaluation of the efﬁcacy of
antioxidant therapies is the use of an appropriate index of
oxidative/nitrosative damage capable of identifying subjects
who could beneﬁt from treatment and which could monitor the
in-vivo antioxidant effect. In order to function as appropriate
indicators of disease and constitute useful diagnostic/prognostic
tools, biomarkers for oxidative/nitrosative stress have to be stable,
accumulate to detectable concentrations, reﬂect speciﬁc oxidation/
nitroxidation pathways, and possibly correlate with disease
severity (Roberts and Morrow, 1997). The choice of appropriate
biomarkers is extremely important in this ﬁeld, especially given
the impossibility of directly evaluating OS/NS qualitatively and
quantitatively in the brains of living subjects. A blood biomarker
would be widely applicable and reduce the need for invasive,
expensive, or time-consuming testing.
Peripheral assessment for some biomarkers provides conﬂict-
ing results and this is probably due to different assessment
methods, sample preparation and treatment. The standardization
of assessment methods and data reporting are critical to reducing
any inconsistencies between studies. Furthermore, several para-
meters (e.g. diet, lifestyle, comorbidity, drug intake), which affect
OS/NS levels, have not always been taken into consideration. In any
biomarker study it is important in increasing diagnostic speciﬁcity
to consider the stage of the disease and a comparison not only with
healthy controls but also with other neurodegenerative diseases.
Future studies are required to overcome these problems since the
identiﬁcation of the valuable reliable peripheral markers of OS/NS,
used in diagnosing and monitoring the progression of the disease
and drug efﬁcacy in AD patients, is of fundamental importance for
researchers and clinicians. Increased speciﬁcity and sensitivity canalso be enhanced by using a panel of different biochemical indices
(including b-amyloid), and integrating these measures with
neuro-imaging techniques in assessing regional structure, function
and biochemistry of the brain. There currently exists no single
biomarker of excellence for oxidative/nitrosative stress and a set of
such biomarkers, or at least a combination of two of these,
appropriately chosen, together with the antioxidant proﬁle, may
provide the most accurate information regarding the oxidant/
antioxidant balance of the organism, the nutritional needs of the
patient and possible antioxidant strategies (Mariani et al., 2005;
Migliore et al., 2005a).
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